期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤坏死因子-α对人滑膜成纤维细胞白细胞介素-37表达的影响 被引量：8

Effect of TNF-α on expression of IL-37 in human fibroblast-like synovicyte
下载PDF
导出
摘要 目的:探讨肿瘤坏死因子-α(TNF-α)对人滑膜成纤维细胞(human fibroblast-like synovicyte,HFLS)白细胞介素-37(IL-37)表达的影响。方法:不同浓度TNF-α与HFLS作用,作用不同时间后,用实时荧光定量逆转录聚合酶链式反应,检测HFLS中IL-37mRNA的表达。结果:TNF-α上调HFLS的IL-37mRNA表达,并呈一定的时间、剂量依赖关系。结论:TNF-α诱导HFLS的IL-37上调表达,为进一步探索HFLSIL-37参与类风湿关节炎的炎症反应提供了实验依据。 Objective To investigate the expression of interleukin 37 （IL-37） in human fibroblast-like synovicyte （HFLS） modulated by TNF-α. Methods The HFLS were treated with different dose of TNF-α at different time periods. The expressions of IL-37 mRNA in HFLS were detected by reverse transcriptase-eonpled quantitative real-time PCR （real-time RT-PCR） analysis. Results The results showed that TNF-α could up- regulate the HFLS IL-37 mRNA expression, which had time-and dose-dependent relationship. Conclusion TNF-α induces IL-37 expression in HFLS, which provides the experiment basis for further study of the potential involvement of HFLS IL-37 in the inflammation response of rheumatoid arthritis.
作者 柯庆喜 张志伟 赵付前 何玲鸽 陈章权
机构地区 广东医学院医学检验学院.广东省医学分子诊断重点实验室
出处 《实用医学杂志》 CAS 北大核心 2013年第5期691-693,共3页 The Journal of Practical Medicine
关键词 肿瘤坏死因子-Α IL-37 滑膜成纤维细胞 Tumor necrosis factor-alpha Interleukin-37 Fibroblast-like synovicyte
分类号 R346 [医药卫生—基础医学]
  • 相关文献

参考文献7

  • 1Boraschi D, Lueehesi D, Hainzl S, et al. IL-37: a new anti- inflammatory cytokine of the IL-1 family [J]. Eur Cytokine Netw, 2011,22(3) : 127-147.
  • 2Nold M F, Nold-Petry C A, Zepp J A, et al. IL-37 is a fundamental inhibitor of innate immunity [ J ]. Nat Immunol, 2010,11(11) : 1014-1022.
  • 3Bartok B, Firestein G S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis [ J ]. Immunol Rev, 2010, 233 ( 1 ) : 233-255.
  • 4Noss E H, Brenner M B. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis [J]. Immunol Rev, 2008,223 ( 1 ) : 252-270.
  • 5Hitchon C A, El-Gabalawy H S. The synovium in rheumatoid arthritis [J ]. Open Rheumatol J, 2011,5 (s1) : 107-114.
  • 6Bulau AM, Fink M, Maucksch C, et al. In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin a-induced hepatitis [J]. Scientific World J, 2011,11 (12) : 2480-2490.
  • 7张挺,李永吉,朱小春.肿瘤坏死因子拮抗剂在类风湿关节炎中的应用进展[J].实用医学杂志,2012,28(4):523-525. 被引量：8

二级参考文献14

  • 1Brown A K,Quinn M A,Karim Z,et al.Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic dug-induced clinical remission:evidence from an imaging study may explain structural progression[J].Arthritis Rheum,2006,54 (12):3761-3773.
  • 2Van der Heijde D,Klareskog L,Landewe R,et al.Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis[J].Arthritis Rheum,2007,56(12):3928-3939.
  • 3Tracey D,Klareskog L,Sasso E H,et al.Tumor necrosis factor antagonist mechanisms of action:a comprehensive review[J].Phannacol Ther,2008,117(2):244-279.
  • 4Zidi I,Mcstiri S,Bartegi A,et al.TNF-alpha and its inhibitors in cancer[J].Med Oncol,2010,27(2):185-198.
  • 5Veronese F M,Mero A.The impact of PEGylation on biological therapies[J].Bio Drugs,2008,22(5):315-329.
  • 6Nesbitt A,Fossati G,Bergin M,et al.Mechanism of action of certolizumab pegol (CDP870):in vitro comparison with other anti-tumor necrosis factor alpha agents[J].Inflamm Bowel Dis,2007,13(11):1323-1332.
  • 7Nesbitt A,Fossati G,Brown D.Effect of structure of conventional anti-TNF and certolizumab pegol on mode of action in rheumatoid arthritis[J].Ann Rheum Dis,2007,66(suppl II):296.
  • 8Oussalah A,Bigard M A,Peyrin-Biroulet L.Certolizumab use in pregnancy[J].Gut,2009,58(4):608.
  • 9Berthelot J M,De Bandt M,Goupille P,et al.Exposition to anti-TNF drugs during pregnancy:outcome of 15 cases and review of the literature[J].Joint Bone Spine,2009,76(1):28-34.
  • 10Choy E H,Hazieman B,Smith M,el al.Efficacy of a novel PEGylated humanized anti-TNF fragment(CDP870) in patients with rheumatoid arthritis:a phase Ⅱ double-blinded,randomized,dose-escalating trial[J].Rheumatology (Oxford),2002,41(10):1133-1137.

共引文献7

同被引文献80

  • 1王燕,窦恒利,曹伟娟,钱琤,梁艳,杨再兴,陆慧琦,朱烨,周晔,仲人前.人TACI-linker-BR3双受体融合基因真核表达载体构建及其在COS-7细胞中的表达[J].第二军医大学学报,2006,27(11):1190-1195. 被引量：1
  • 2Sharma S, Kulk N, Nold MF, et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cy- tokines[J]. J Immunol, 2008,180(8) :5477-5482.
  • 3Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: a new anti-in- flammatory cytokine of the IL-1 family [ J ]. Eur Cytokine Netw, 2011,22(3) :127-147.
  • 4Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity [ J]. Nat Immunol, 2010,11 ( 11 ) : 1014-1022.
  • 5Song L, Qiu F, Fan Y, et al. Glucocorticoid regulates interleukin- 37 in systemic lupus erythematosus[J]. J Clin Immunol, 2013,33 (1) :111-117.
  • 6McNamce EN, Masterson JC, Jedlicka P, et al. Interleukin 37 ex- pression protects mice from colitis [ J ]. Proc Natl Acad Sci USA, 2011,108 (40) :16711-16716.
  • 7Busfield SJ, Comrack CA, Yu G, et al. Identification and gene or- ganization of three novel members of the IL-1 family on human chromosome 2[ J ]. Genomics, 2000,66(2) :213-216.
  • 8Smith DE, Renshaw BR, Ketchem RR, et al. Four new members expand the interleukin-1 superfamily[ J]. J Biol Chem, 2000,275 (2) :1169-1175.
  • 9Imaeda H, Takahashi K, Fujimoto T, et al. Epithelial expression of interleukin-37b in inflammatory bowel disease[J]. Clin Exp Im- munol, 2013,172(3) :410-416.
  • 10Kumar S, McDonnell PC, Lehr R, et al. Identification and initial characterization of four novel members of the interleukin-1 family [J]. J Biol Chem, 2000,275(14) :10308-10314.

引证文献8

二级引证文献27

实用医学杂志
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部